M&T Bank
MTB
$215.28
-1.54%
M&T Bank Corporation is a Buffalo, New York-based regional bank holding company with roughly $220 billion in assets, operating over 900 branches across 13 states and Washington, D.C., primarily in New England and the Mid-Atlantic. It provides retail and commercial banking, wealth management through Wilmington Trust, an LPL Financial partnership, and a corporate trust business, positioning it as a relationship-driven community banking franchise rather than a capital-markets-heavy money-center bank. The current investor narrative centers on net interest income resilience as deposit costs reprice lower against a sticky loan book, with the Q2 2026 quarter showing revenue growth of roughly 2% year over year and net income of $818 million. Debate is split between bulls who see a low-beta, dividend-rich value name trading near tangible book with improving profitability, and skeptics who point to a stock that has lagged the broader market over the past three and six months amid credit-quality and net interest margin concerns across regional banks.…
MTB
M&T Bank
$215.28
Related headlines
Investment Opinion: Should I buy MTB Today?
Rating: Hold. The core thesis is that MTB is a cheap, low-beta, dividend-paying regional bank whose profitability is improving but whose revenue growth (2.07% year over year) and momentum (-13.63% over three months) are too weak to justify adding exposure before the margin recovery is confirmed. The consensus recommendation of hold (mean 2.68 across 20 analysts) and the $250.28 average target, implying 16.3% upside, frame the stock as fairly valued with a modest positive skew rather than a compelling entry.
Supporting evidence is mixed but leans value-positive. Valuation is undemanding at 11.85x trailing and 10.23x forward earnings, 1.08x book, 2.56x sales, and 0.76 PEG, all consistent with a bank priced for skepticism. Profitability is genuinely improving: Q2 2026 net income of $818 million on a 24.35% net margin, gross margin of 71.79%, and operating margin of 37.71%, with diluted EPS of $5.23 versus $4.24 a year earlier. Cash generation is strong at $3.68 billion trailing free cash flow (~11.7% FCF yield), funding a 3.31% dividend yield at a 36.65% payout ratio plus $460 million of quarterly buybacks. The offset is that ROE of 9.77% and revenue growth of 2.07% are below what typically drives multiple expansion, and the 16.3% target upside is not backed by consensus conviction.
Key risks that could invalidate the thesis are a stall in deposit-cost repricing that reverses the Q2 margin gain, a credit-quality deterioration in the commercial book, and continued relative underperformance that forces analyst downgrades. This Hold would upgrade to Buy if net margin holds above 24% for another quarter and ROE moves above 11%, or if the stock reclaims $240 and breaks the pattern of lower highs. It would downgrade to Sell if revenue growth turns negative, net margin falls back below 21%, or the stock breaks decisively below $204. On balance, MTB is fairly valued to modestly undervalued relative to its own history (11.85x PE sits mid-range versus a 10.2x-13.4x recent band) and cheap versus the market, but not yet a compelling buy given the momentum breakdown.
Sign up to view all
MTB 12-Month Price Forecast
MTB presents a classic value-versus-catalyst standoff: the stock is cheap on every metric (11.85x trailing PE, 1.08x book, 0.76 PEG) and profitability is improving, yet the price action and consensus rating argue that the market is waiting for proof the margin recovery is durable. The 50% base-case probability reflects that the most likely outcome is range-bound trading between the $224 low target and $250 average target while the company delivers another quarter or two of stable margins. I would upgrade to bullish if Q3 2026 shows net margin above 24% and ROE above 11%, or if the stock reclaims $240 and breaks the lower-highs pattern. I would downgrade to bearish if net margin falls back below 21%, revenue growth turns negative, or the stock breaks below $204, which would open the path to the $176 low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on M&T Bank's 12-month outlook, with a consensus price target around $249.32 and implied upside of +15.8% versus the current price.
Average Target
$249.32
0 analysts
Implied Upside
+15.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$224 - $301
Analyst target range
Coverage is broad with 20 analysts, but sentiment is tepid: the consensus recommendation is "hold" with a mean rating of 2.68 (where 1 is strong buy and 5 is strong sell), and the average target price of $250.28 implies roughly 16.3% upside from the current $215.28. The distribution skews neutral-to-cautious — recent actions include Morgan Stanley upgrading to Overweight on September 8, 2026, and reiterating on September 28, while Truist, UBS, JP Morgan, Barclays, KBW, and DA Davidson all sit at Hold/Neutral/Market Perform — so the consensus leans neutral with a modest bullish tilt from the target price rather than conviction buying. The target range is wide, from $224 to $301, a spread of about 34% of the current price, which signals meaningful disagreement about the earnings trajectory. The high target of $301 would require multiple expansion toward 13x forward earnings plus confidence in net interest margin recovery and credit stability — essentially a re-rating back toward the stock's 2026 highs and beyond; the low target of $224 implies only about 4% upside and prices in margin compression, flat loan growth, and continued relative underperformance. The consensus forward EPS estimate of $22.66 (range $21.18-$23.44) and revenue estimate of $10.87 billion (range $10.63-$11.25 billion) are tightly clustered, suggesting analysts agree on near-term fundamentals but diverge on the appropriate multiple — a classic value-versus-catalyst debate for a low-beta regional bank.
Drowning in data?
Find the real signal!
Bulls vs Bears: MTB Investment Factors
The bear case currently has stronger near-term evidence: the stock has lost 13.63% in three months, underperformed SPY by 16.32% over that window, and trades below a falling 50-day trend with lower highs intact. The bull case rests on valuation and profitability — 10.23x forward earnings, 1.08x book, a 24.35% net margin, and 16.3% upside to the average analyst target — but those are static advantages that have not yet arrested the price decline. The single most important tension is whether the Q2 2026 margin expansion (net margin 24.35% versus 20.59% in Q1) is the start of a durable net interest margin recovery or a one-quarter bounce that reverses as deposit competition returns. If margins hold and ROE pushes toward 12%, the 1.08x book multiple re-rates toward its 1.33x peak; if margins compress, the stock drifts back toward tangible book and the $176 low.
Bullish
- Deep value on earnings and book: At 11.85x trailing and 10.23x forward earnings, with a 1.08x price-to-book and 0.76 PEG, MTB trades at a discount that already prices in regional-bank skepticism. The 3.31% dividend yield with a 36.65% payout ratio adds a tangible income cushion while waiting for a re-rating.
- Profitability inflecting upward: Q2 2026 net income of $818 million produced a 24.35% net margin, up sharply from 20.59% in Q1 2026 and 21.75% in Q2 2025. Diluted EPS rose to $5.23 from $4.24 a year earlier, and the operating margin expanded to 37.71%, showing the deposit-cost repricing is flowing through.
- Analyst targets imply double-digit upside: The $250.28 average target across 20 analysts represents 16.3% upside from $215.28, and even the low target of $224 implies about 4% upside. Morgan Stanley's upgrade to Overweight in September 2026 suggests sentiment may be turning at the margin.
- Low beta with strong cash generation: A beta of 0.615 makes MTB roughly 40% less volatile than the S&P 500, and $3.68 billion of trailing free cash flow against a $31.5 billion market cap equates to an ~11.7% FCF yield. Q2 2026 operating cash flow of $1.27 billion comfortably covered $256 million of dividends and $460 million of buybacks.
Bearish
- Momentum has broken down: The stock is down 13.63% over three months and 4.75% over one month, with relative strength versus SPY at -16.32% and -5.97% respectively. The sequence of lower highs from $255.95 in August to roughly $240 in September to $215 now is characteristic of distribution, not a healthy pullback.
- Revenue growth is anemic: Q2 2026 revenue of $3.36 billion grew only 2.07% year over year, below nominal GDP and far short of what justifies multiple expansion. The quarterly revenue path ($3.171B, $3.292B, $2.513B, $3.333B, $3.225B, $3.360B) shows no acceleration, leaving earnings growth dependent on margin and buybacks rather than top-line expansion.
- ROE below top-tier bank thresholds: A 9.77% return on equity sits below the 12%+ level that typically supports a premium to tangible book. With price-to-book at 1.08x, the market is effectively paying a slight premium for sub-par returns, which caps re-rating potential unless ROE moves into double digits.
- Consensus is only a hold: The mean recommendation of 2.68 across 20 analysts is firmly neutral, with Truist, UBS, JP Morgan, Barclays, KBW, and DA Davidson all at Hold/Neutral/Market Perform. The wide $224-$301 target range (34% of the current price) signals genuine disagreement about the earnings trajectory rather than conviction.
MTB Technical Analysis
MTB is in a medium-term downtrend that has interrupted a still-positive one-year trend: the stock is up 20.52% over the trailing year but has fallen 13.63% over three months and 4.75% over the past month, with a YTD gain of just 5.51%. At $215.28, the shares sit at roughly 84% of the 52-week range (low $176.02, high $255.95), meaning they are in the upper-middle of the band but well off the highs — a positioning that reflects fading momentum rather than a value washout or a breakout setup. The 52-week high of $255.95 was set in mid-August, and the failure to hold that level marks the current consolidation as distribution rather than accumulation. Recent momentum is clearly decelerating and diverging from the longer-term trend: the 1-month change of -4.75% and 3-month change of -13.63% contrast sharply with the +20.52% 1-year return, and relative strength versus SPY is negative across every short window (-5.97% over 1 month, -16.32% over 3 months, -9.08% over 6 months) even as the 1-year relative strength remains +4.99%. This divergence — long-term outperformance eroding from the front — typically signals either a mean-reversion pullback within an uptrend or the early stage of a trend reversal, and the sequence of lower highs since August (from $255.95 to roughly $240 in September to $215 now) leans toward the latter until proven otherwise. Volume of about 2.04 million shares and a short ratio of 4.63 days suggest no aggressive bearish positioning, so the decline looks more like steady institutional de-risking than a short-driven collapse. Key levels are well defined: support sits at the 52-week low of $176.02, with intermediate support around the $204-$208 zone where the stock found buyers in May, while resistance is the $255.95 high, with a nearer ceiling near $240 where the September rally stalled. A decisive break below $204 would confirm the downtrend and open a path toward the $176 low, whereas reclaiming $240 would signal the pullback was corrective and re-establish the uptrend toward the highs. With a beta of just 0.615, MTB is roughly 40% less volatile than the S&P 500, which cushions drawdowns but also means rallies are slower — position sizing can be larger than for high-beta names, though the -17.55% max drawdown shows the stock is not immune to sharp regional-bank selloffs.
Beta
0.61
0.61x market volatility
Max Drawdown
-17.6%
Largest decline past year
52-Week Range
$179-$256
Price range past year
Annual Return
+20.5%
Cumulative gain past year
| Period | MTB Return | S&P 500 |
|---|---|---|
| 1m | -4.7% | +0.2% |
| 3m | -13.6% | +2.9% |
| 6m | -1.6% | +8.4% |
| 1y | +20.5% | +14.9% |
| ytd | +5.5% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MTB Fundamental Analysis
Revenue is growing but at a modest, decelerating pace: Q2 2026 revenue of $3.36 billion rose 2.07% year over year from $3.292 billion in Q2 2025, continuing a multi-quarter pattern of low-single-digit expansion (Q1 2026 at $3.225 billion, Q4 2025 at $3.333 billion, Q3 2025 at $2.513 billion). The segment mix shows retail banking as the largest contributor at $1.21 billion, followed by commercial banking at $752 million, institutional services and wealth management at $384 million, and all other at $186 million — a diversified, deposit-funded model where growth depends more on net interest margin and loan demand than on any single high-growth line. The trajectory implies a mature, rate-sensitive franchise: revenue is not collapsing, but 2% growth is below nominal GDP and well short of what would justify multiple expansion without margin help. Profitability is solid and improving: Q2 2026 net income of $818 million on a 24.35% net margin, with gross margin at 71.79% and operating margin at 37.71%, up from a 20.59% net margin in Q1 2026 and 21.75% in Q2 2025. The sequential earnings progression — EPS of $3.33 (Q1 2025), $4.24 (Q2 2025), $4.82 (Q3 2025), $4.67 (Q4 2025), $4.24 (Q1 2026), $5.23 (Q2 2026) — shows a clear upward trend despite quarterly noise, and the 23.16% trailing net margin is healthy for a regional bank. The main caveat is that the reported EPS of $0.09 in the key-metrics feed conflicts with the $5.23 quarterly diluted figure, likely a data artifact, so investors should anchor on the income statement; the forward EPS estimate of $22.66 implies continued earnings power. Balance-sheet health is adequate but not fortress-like: debt-to-equity of 0.448 is moderate for a bank, ROE of 9.77% is below the 12%+ level top-tier peers target, and ROA of 1.41% is respectable. Free cash flow of $3.682 billion TTM against a $31.5 billion market cap implies a roughly 11.7% FCF yield, and Q2 2026 operating cash flow of $1.268 billion comfortably funded $256 million of dividends and $460 million of buybacks, while the current ratio of 0.32 reflects the bank's deposit-funded model rather than a liquidity problem. The 3.31% dividend yield with a 36.65% payout ratio is well covered, and the company is returning capital internally without heavy external financing dependence.
Quarterly Revenue
$3.4B
2026-06
Revenue YoY Growth
+2.1%
YoY Comparison
Gross Margin
71.8%
Latest Quarter
Free Cash Flow
$3.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MTB Overvalued?
Because MTB is profitable (Q2 2026 net income of $818 million), the PE ratio is the primary metric: the stock trades at 11.85x trailing earnings and 10.23x forward earnings, and the gap between the two implies the market expects modest EPS growth — consistent with the $22.66 consensus forward EPS versus the current run-rate. A trailing PE near 12x is inexpensive in absolute terms and reflects the market's skepticism about regional-bank earnings durability rather than a broken business. Peer comparison is constrained by the absence of a formal industry-average dataset in the provided valuation inputs, but the internal multiples are telling: price-to-book of 1.08x, price-to-sales of 2.56x, PEG of 0.76, and EV/EBITDA of 6.17x all sit at value-oriented levels for a bank with a 23% net margin and 3.3% dividend yield. The 1.08x P/B is the key anchor — regional banks with sub-10% ROE typically trade near or below tangible book, so MTB's slight premium is justified only if ROE (currently 9.77%) improves toward double digits; the 0.76 PEG suggests the stock is cheap relative to its growth, but that growth is only ~2% on revenue. Historically, MTB's PE has ranged from about 6.1x (Q2 2023) to 36.9x (Q2 2022, an earnings-depressed quarter), with the recent band clustering between roughly 10.2x and 13.4x over the past several quarters; at 11.85x the stock sits in the middle of its own recent range, neither a historical bargain nor an overextended level. The P/B of 1.08x is near the low end of its multi-year range (which peaked around 1.33x in Q2 2026 and troughed near 0.79x in 2023), suggesting the market is pricing in cautious expectations rather than optimism — a setup where improving margins or credit could drive re-rating, but where deterioration would push shares toward book value.
PE
11.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 7x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin durability and return levels. Interest expense of $828 million in Q2 2026 consumed roughly 25% of revenue, and the 2.07% revenue growth rate leaves little buffer if deposit costs stop falling. ROE of 9.77% is below the 12%+ threshold that supports premium book valuations, and the 0.32 current ratio reflects a deposit-funded model where a funding shock would transmit directly to earnings. The reported EPS of $0.09 in the key-metrics feed conflicts with the $5.23 diluted figure, a data-quality issue that could distort screening and sentiment. Finally, the 36.65% payout ratio and $256 million quarterly dividend commitment mean a prolonged earnings slump would pressure capital return.
Market and competitive risks are dominated by valuation compression and sector rotation. At 11.85x trailing earnings and 1.08x book, MTB is not expensive in absolute terms, but regional banks as a group are exposed to credit-quality headlines and net interest margin anxiety, which is precisely what has driven the 13.63% three-month decline. The beta of 0.615 cushions broad market selloffs, but the -17.55% max drawdown shows the stock is not immune to regional-bank-specific shocks. Recent peer news — Citigroup beating on higher net interest income but falling on declining capital ratios and rising credit provisions — illustrates how quickly investors punish capital and credit signals even when earnings beat. With the consensus at hold and a 34% spread between the $224 low and $301 high target, any negative credit datapoint could trigger a wave of downgrades.
Worst-case scenario: a credit-quality deterioration in the commercial real estate or commercial book combines with a stall in deposit repricing, compressing net interest margin and pushing EPS below the $21.18 low estimate. In that chain, the stock would break the $204-$208 intermediate support, confirm the downtrend, and retest the 52-week low of $176.02 — a decline of roughly 18% from $215.28. A more severe outcome, consistent with the -17.55% max drawdown and a move toward the 2023 trough book multiple of 0.79x, would imply a price near $157, or about -27% from current levels. The realistic downside band is therefore -18% to -27%, with the low analyst target of $224 (+4%) representing the mild version of the bear case.
FAQ
The most severe risk is credit-quality deterioration in the commercial and commercial real estate books, which would force provision builds and could push EPS below the $21.18 low estimate, driving the stock toward the $176.02 low. Second is margin risk: interest expense of $828 million in Q2 2026 remains heavy, and if deposit-cost repricing stalls, the 24.35% net margin could reverse toward the 20.59% Q1 level. Third is valuation and momentum risk — the 13.63% three-month decline and -16.32% relative strength versus SPY show the market is already de-risking, and a break below $204 support would confirm the downtrend. Fourth is company-specific execution risk around the 9.77% ROE, which is below the 12%+ level needed to justify the 1.08x book multiple, leaving little cushion if returns disappoint.
The 12-month forecast has three scenarios: a 25% bull case targeting $270-$301 if net interest margin recovery proves durable and ROE pushes toward 12%, a 50% base case targeting $224-$250 if revenue growth stays near 2-3% and margins hold, and a 25% bear case targeting $176-$204 if credit deteriorates or deposit repricing stalls. The base case is most likely, anchored on the $250.28 average analyst target and the $22.66 consensus EPS estimate, implying the stock trades in its recent valuation band. The key assumption behind the base case is that the Q2 2026 net margin of 24.35% holds above 22% without further expansion, keeping EPS near consensus while the dividend and buyback support the price.
MTB looks modestly undervalued on absolute metrics: 11.85x trailing and 10.23x forward earnings, 1.08x price-to-book, 2.56x price-to-sales, and a 0.76 PEG all sit at value-oriented levels for a bank with a 23.16% trailing net margin. Relative to its own history, the 11.85x PE sits in the middle of the recent 10.2x-13.4x band, neither a bargain nor overextended, while the 1.08x book is near the low end of its multi-year range versus a 1.33x peak. The market is pricing in caution — sub-10% ROE and 2.07% revenue growth justify the discount rather than a premium. A re-rating toward 13x forward earnings would imply roughly $295 per share, but that requires confidence in margin recovery that the current price does not reflect.
From a risk/reward perspective, MTB offers 16.3% upside to the $250.28 average analyst target against roughly 18% downside to the $176.02 52-week low, a roughly balanced skew that argues for patience rather than aggressive accumulation. The valuation is undemanding at 10.23x forward earnings and 1.08x book, and the 3.31% dividend yield with a 36.65% payout ratio provides income while waiting. However, the stock is down 13.63% over three months with relative strength versus SPY at -16.32%, and the consensus rating is only a hold (2.68 mean). It is a reasonable buy for income-focused, low-beta investors with a 12-18 month horizon who can tolerate a retest of $204, but momentum-oriented investors should wait for a reclaim of $240 before committing.
MTB is better suited to a long-term holding period of at least 12-18 months than to short-term trading. Its beta of 0.615 means rallies are slow and drawdowns are cushioned, so short-term momentum trades offer limited payoff, while the 3.31% dividend yield and 36.65% payout ratio reward patient ownership. The stock is in a medium-term downtrend with lower highs since August, making near-term entry timing difficult, but the 1.08x book valuation and improving profitability provide a reasonable long-term risk/reward. A concrete minimum holding period of 12 months allows time for the margin recovery to be confirmed across two to three quarters and for the multiple to re-rate toward the $250 average target.
